Document type: Toolkit Practice area: Intellectual Property — Patents Jurisdiction: United States (federal) Last reviewed: 5 September 2026

1. Patent estate mapping worksheet

There is no Orange Book. This worksheet replaces it, and it takes weeks rather than minutes.

REFERENCE PRODUCT: __________  BLA No.: __________
First licensure date: __________
12-year exclusivity expires: __________
4-year submission bar expires: __________
Pediatric exclusivity: __________
Prepared by: __________  Updated: __________

PATENT INVENTORY
| Patent | Category | Claims (summary) | Expiry | PTE? |
  Terminal disclaimer? | Our process implicates? | Design-
  around available? | Priority |

CATEGORIES TO COVER
[ ] Composition of matter (molecule, glycoforms, variants)
[ ] Cell line and expression system
[ ] Culture media and feeding strategy
[ ] Bioreactor process conditions
[ ] Harvest and clarification
[ ] Purification (chromatography, viral inactivation)
[ ] Formulation (buffers, stabilizers, surfactants, conc.)
[ ] Device and presentation (autoinjector, PFS, on-body)
[ ] Method of use — one row per approved indication
[ ] Analytical methods
[ ] Manufacturing quality and release testing

SEARCH SOURCES
[ ] Assignee search (sponsor and all affiliates)
[ ] Inventor searches (key scientists)
[ ] Family searches on every hit
[ ] Pending applications and published applications
[ ] Foreign counterparts (claims may differ)
[ ] Litigation and IPR history
[ ] Standards and scientific literature naming the sponsor

SUMMARY
Total patents identified: ______
Expiring before our target entry: ______
Implicated by our current process: ______
Design-around available for: ______
**PATENTS THAT ACTUALLY CONTROL OUR DATE: ______**

Drafting notes.

The last line is the point. A hundred-patent inventory is unmanageable; the ten that control the date are the program.

"Design-around available?" must be answered by process development, not by counsel. This column is the interface between the legal and technical programs and it is where the value is created.

Update it quarterly. Continuations issue throughout development, and a patent that appears in year two changes the analysis.

2. Process design-around record

The single most valuable document in a biosimilar patent defense. Created during development, not during litigation.

PROCESS DESIGN DECISION RECORD
Program: __________  Unit operation: __________
Date: __________  Prepared by: __________

1. THE PATENT AT ISSUE
   Patent No.: ______  Claim(s): ______
   Claim scope as we understand it: ______________________
   Counsel's analysis dated: ______

2. THE APPROACH WE CONSIDERED AND REJECTED
   Description: ____________________________________
   Why it would fall within the claim: ______________
   Technical performance: __________________________

3. THE APPROACH WE ADOPTED
   Description: ____________________________________
   How it differs from the claim: __________________
   Which limitation is not met, and why: ____________
   Technical performance: __________________________
   Cost and schedule impact: $________ / ______ months

4. COMPARABILITY IMPACT
   Effect on the comparability package: ______________
   Regulatory affairs sign-off: ______  Date: ______

5. SIGN-OFFS
   Process development: __________  Date: ______
   Patent counsel: __________  Date: ______

Drafting notes.

Section 3's "which limitation is not met" is the non-infringement case, written years before it is needed, by the people who actually made the decision.

Section 3's cost line matters at trial. A company that spent $14 million and eight months to avoid a patent was not indifferent to it, and that fact answers the argument that the design-around was a litigation-driven afterthought.

Keep these in the development file, not the legal file. They are ordinary business records made in the ordinary course, which is what gives them weight — and counsel's analysis referenced in section 1 stays privileged and separate.

3. Dance decision memorandum

PRIVILEGED — ATTORNEY WORK PRODUCT
BPCIA DISCLOSURE DECISION — [Program]
Prepared by: __________  Date: __________ (before Day 20)

1. THE DECISION
   [ ] Provide the application and process information under
       42 U.S.C. § 262(l)(2)(A)
   [ ] Decline

2. IF WE DANCE — WHAT WE GAIN
   Narrowing: sponsor's estate is ______ patents; the immediate
   action would likely cover ______.
   Information: the sponsor's detailed statements at steps 4
   and 6 disclose its infringement and validity theories.
   Sequencing: held-back patents proceed on a preliminary
   injunction posture where the sponsor bears the burden.

3. IF WE DANCE — WHAT WE DISCLOSE
   The 351(k) application.
   The manufacturing process description.
   ASSESSED TRADE SECRET EXPOSURE: ______________________
   [Which specific know-how? What would a competitor do with
   it? Is it independently discoverable? Is it patented by us?]
   Protection available: statutory floor at § 262(l)(1) plus a
   negotiated supplemental agreement.

4. IF WE DECLINE — THE CONSEQUENCE
   Submission is an act of infringement as to ANY patent that
   could have been listed — 35 U.S.C. § 271(e)(2)(C)(ii).
   Sponsor may bring a DJ action on any patent claiming the
   product or a use — 42 U.S.C. § 262(l)(9)(C).
   No injunction compels disclosure — Sandoz v. Amgen.
   Estimated patents the sponsor would assert: ______
   Estimated additional litigation cost: $________

5. RECOMMENDATION AND REASONING

6. APPROVALS
   General Counsel: ______  Business lead: ______

Drafting notes.

Section 3's exposure assessment must be specific. "Our process is confidential" is not an analysis. Which know-how, what would a competitor do with it, and is it independently discoverable from the product?

Section 4's patent count is the comparison that decides the question. If the sponsor realistically has six assertable patents and the dance would narrow to three, the calculus is different than if it has sixty.

Prepare this before day 20 and keep it. The decision gets questioned later, by the board and sometimes by a court.

4. Manufacturing process disclosure — scope guide

DISCLOSURE SCOPE — 42 U.S.C. § 262(l)(2)(A)
"information that describes the process or processes used to
manufacture the biological product"

INCLUDE
[ ] Cell line identity at the level the application describes
[ ] Upstream process: culture format, scale, general feeding
    approach, harvest trigger
[ ] Downstream process: the sequence of unit operations, the
    chromatography modes used, viral clearance steps
[ ] Formulation composition as in the application
[ ] Fill-finish approach and presentation
[ ] Release testing methods at the application level

CONSIDER CAREFULLY — DISCLOSE ONLY IF THE STATUTE REQUIRES
[ ] Specific media compositions and proprietary supplements
[ ] Precise feeding schedules and setpoint profiles
[ ] Resin selections and specific ligand chemistries
[ ] Buffer compositions and gradient profiles
[ ] Process control strategies and PAT approaches
[ ] Yields and productivity data

DO NOT INCLUDE (unless separately required)
[ ] Batch records
[ ] Vendor identities and supply agreements
[ ] Cost data
[ ] Development history and failed approaches
[ ] Internal quality investigations

PREPARED BY: technical author ______  counsel review ______
DISCLOSURE LOG MAINTAINED: [ ] Yes  Location: __________

Drafting notes.

The middle category is the judgment. The statute requires information describing the process; it does not require the batch record. Where a process patent turns on a specific parameter, disclosing that parameter is likely required to permit an assessment — and disclosing every parameter is not.

Have counsel review before it goes. Once disclosed, it cannot be recalled, and the applicant's competitor holds it.

Maintain the log. You will need to know precisely what was disclosed when a dispute arises about scope or about the sponsor's use of it.

5. Supplemental confidentiality agreement — key terms

Propose this with the day-20 disclosure.

SUPPLEMENTAL CONFIDENTIALITY AGREEMENT
Supplementing 42 U.S.C. § 262(l)(1)

1. SCOPE. This Agreement supplements and does not limit the
statutory protections. In the event of conflict, the greater
protection applies.

2. DESIGNATION TIERS.
   (a) CONFIDENTIAL — recipients permitted by § 262(l)(1)(B).
   (b) HIGHLY CONFIDENTIAL — OUTSIDE COUNSEL AND EXPERTS ONLY
       — the manufacturing process description and any
       document derived from it. NOT the in-house
       representative.

3. PROSECUTION BAR. No person receiving HIGHLY CONFIDENTIAL
information shall, during the engagement and for [two] years
thereafter, participate in drafting, amending, or prosecuting
any patent application relating to [defined field].

4. EXPERTS. Each expert shall be identified to Applicant [7]
days before disclosure, with a CV and a list of engagements
with competitors of Applicant in the past [five] years.
Applicant may object on stated grounds.

5. USE. Solely to assess whether a claim of patent infringement
could reasonably be asserted and for litigation arising from
this application. NOT for any business, competitive,
regulatory, or product development purpose.

6. FILING. Under seal, per the court's procedures.

7. CLAWBACK. Inadvertent production does not waive privilege or
protection; return or destroy on notice.

8. SUBPOENA. Notice to Applicant [10] business days before any
production compelled by third-party process.

9. RETURN OR DESTRUCTION. Within [30] days of conclusion,
except one archival copy held by outside counsel.

10. SURVIVAL. Sections 3, 5, and 9 survive termination.

Drafting notes.

Paragraph 2(b) is the provision worth fighting for. The statute permits one in-house representative to see everything; a tiered designation keeps the process description away from anyone inside the sponsor's organization.

Paragraph 4's expert vetting matters because the natural expert in a narrow biologics field may be a former employee of a competitor.

Paragraph 3's prosecution bar protects both sides and should be mutual.

6. Sponsor's patent list

LIST OF PATENTS UNDER 42 U.S.C. § 262(l)(3)(A)
[Sponsor] to [Applicant]  —  [Reference Product]
Date: __________  (Due Day 80)

Pursuant to 42 U.S.C. § 262(l)(3)(A), [Sponsor] identifies the
following patents for which it believes a claim of patent
infringement could reasonably be asserted if a person not
licensed engaged in the making, using, offering to sell,
selling, or importing of the biological product described in
your application.

| No. | Patent | Title | Expiry | Category | Would license? |
|  1  | ______ | ____  | _____  | Formulation | No |
|  2  | ______ | ____  | _____  | Purification process | No |
| ... |
|  8  | ______ | ____  | _____  | Device | YES — terms below |

PATENTS [SPONSOR] IS PREPARED TO LICENSE
Patents ___ and ___, on the following terms: [field, royalty
basis, term, territory].

RESERVATION. This list is provided under § 262(l)(3)(A) and
does not constitute an admission regarding validity,
enforceability, infringement, or the scope of any claim.

Drafting notes.

The licensing column is a strategic instrument. Offering the device patents while holding the process patents tells the applicant where the fight will be and can narrow the dispute by agreement before step 5.

Over-listing is the temptation and the error. Every patent listed must be one for which infringement "could reasonably be asserted," and a list padded with expired or plainly irrelevant patents damages credibility and supports a fee argument later.

Under-listing is worse. A patent omitted is out of the immediate action, and adding it later means litigating it on a preliminary injunction posture where you bear the burden.

7. Detailed statements — outlines

Applicant's statement (Day 140), per patent:

U.S. PATENT NO. [___] — [Title]

I.   THE CLAIMS AT ISSUE
     [Quote the independent claims.]

II.  NON-INFRINGEMENT
     A. The relevant aspect of Applicant's process/product
        [Describe, by reference to the disclosure provided.]
     B. Claim element analysis
        | Claim limitation | Applicant's process | Met? | Why not |
     C. No infringement under the doctrine of equivalents
        [Address prosecution history estoppel where applicable.]

III. INVALIDITY
     A. Prior art relied upon
     B. Ground 1: [anticipation / obviousness], claim by claim
     C. Ground 2: [written description / enablement /
        indefiniteness]
     D. Obviousness-type double patenting, if applicable

IV.  UNENFORCEABILITY [if applicable]

V.   ALTERNATIVELY, APPLICANT DOES NOT INTEND TO MARKET BEFORE
     EXPIRY [for patents being conceded]

Sponsor's reply (Day 200), per patent:

U.S. PATENT NO. [___]

I.   RESPONSE ON INFRINGEMENT
     A. Claim construction positions
     B. Element-by-element analysis against the disclosed
        process, with citations to the disclosure
     C. Doctrine of equivalents, if applicable

II.  RESPONSE ON VALIDITY
     A. The prior art does not disclose or suggest [limitation]
     B. Secondary considerations [commercial success, long-felt
        need, unexpected results, skepticism, copying]
     C. Response on § 112 grounds

III. RESPONSE ON ENFORCEABILITY

Drafting notes.

These are litigation briefs filed before the complaint. Both sides should draft them as such, because they will be quoted in the case and, sometimes, in a fee motion.

The applicant's section II.B table is the document. A claim chart applied to the actual process is what a sponsor needs to assess, and a conclusory statement invites an inadequacy argument.

The sponsor's section II.B on secondary considerations is worth doing properly here rather than saving for trial; it signals the strength of the position and it occasionally produces a concession.

Concede clearly where you concede. Both sides gain credibility, and the case narrows.

8. List exchange worksheet

For step 6, where negotiation fails.

LIST EXCHANGE ANALYSIS — 42 U.S.C. § 262(l)(5)

MECHANICS
Applicant notifies Sponsor of the number (N) of patents it will
list. The parties then simultaneously exchange lists. Sponsor
may list a number determined by reference to N under
§ 262(l)(5)(B)(ii).

OUR PATENT RANKING (strongest to weakest for us)
1. ______ — why: ______________________
2. ______ — why: ______________________
3. ______ — why: ______________________

THEIR LIKELY RANKING (our assessment)
1. ______  2. ______  3. ______

SCENARIO MODELING
| N chosen | Patents we get | Patents they get | Net position |
|    1     |                |                  |              |
|    2     |                |                  |              |
|    3     |                |                  |              |
|    5     |                |                  |              |

CONSIDERATIONS
- A larger N means more of our patents AND more of theirs.
- Which patents do we most want resolved NOW versus later on a
  preliminary injunction posture (where the SPONSOR bears the
  burden)?
- Litigation cost per additional patent: $________
- Which patents, if held back, would support a strong PI motion?

RECOMMENDED N: ______  Reasoning: __________________

Drafting notes.

The applicant's incentive is subtle. Holding a patent back means litigating it later on a preliminary injunction posture where the sponsor bears the burden of proving likelihood of success and irreparable harm. For a patent where the applicant's defense is strong, that is a better posture.

The sponsor's incentive runs the other way for its strongest patents: resolving them in the immediate action, on a full record, is better than a preliminary injunction on a compressed one.

Model the arithmetic before choosing. The mechanism rewards counting.

9. Notice of commercial marketing

[Date]

[Sponsor]                    [Patent Owner, if different]

Re: Notice of Commercial Marketing under 42 U.S.C.
    § 262(l)(8)(A) — [Product], BLA No. [___]

Dear Sir or Madam:

Pursuant to 42 U.S.C. § 262(l)(8)(A), [Applicant] hereby
provides notice that it intends to commence commercial
marketing of [product name], a biosimilar to [reference
product], not earlier than 180 days from the date of this
notice.

[If not yet licensed:] [Applicant]'s application under 42
U.S.C. § 262(k) is pending before the Food and Drug
Administration. As the Supreme Court held in Sandoz Inc. v.
Amgen Inc., 582 U.S. 1 (2017), this notice may be given before
licensure.

Please direct any communications to the undersigned.

Very truly yours,

Drafting notes.

Send it as early as the commercial plan permits. Running the 180 days concurrently with the tail of FDA review is worth six months of revenue on a major product, and Sandoz expressly permits it.

Document receipt. The launch date depends on it, and the sponsor's injunction window runs from it.

Do not include more than the statute requires. This is a notice, not a submission.

10. Preliminary injunction — outline and evidence plan

Sponsor's motion:

MOTION FOR PRELIMINARY INJUNCTION
42 U.S.C. § 262(l)(8)(B); Fed. R. Civ. P. 65

I.   INTRODUCTION
II.  BACKGROUND
     The reference product; the patents; the dance; the notice.
III. LIKELIHOOD OF SUCCESS
     A. Infringement of the '___ patent
     B. The validity challenges do not raise a substantial
        question
IV.  IRREPARABLE HARM
     A. Price erosion is immediate and permanent
     B. Formulary displacement cannot be reversed
     C. Market share loss compounds
     D. Sponsor has never licensed these patents
     E. Damages cannot be calculated in the counterfactual
V.   BALANCE OF EQUITIES
VI.  PUBLIC INTEREST
VII. BOND

Irreparable harm evidence plan — start when the application is accepted:

| Evidence | Source | Lead time | Owner | Status |
| Net price trajectory modeling | Economist | 8 weeks | | |
| Analogous product case studies | Economist | 6 weeks | | |
| Formulary displacement data | Market access | 6 weeks | | |
| Payer switching irreversibility | Market access + | 8 weeks | | |
|   testimony | payer witness | | | |
| Share loss modeling with/without | Economist | 6 weeks | | |
|   interchangeability | | | | |
| Licensing history declaration | In-house counsel | 2 weeks | | |
| Manufacturing and supply impact | Operations | 4 weeks | | |
| Investment and R&D consequences | Finance | 4 weeks | | |

Applicant's opposition:

I.   INTRODUCTION
II.  NO LIKELIHOOD OF SUCCESS
     A. Substantial question of non-infringement
        [The design-around record does the work here.]
     B. Substantial question of invalidity
III. NO IRREPARABLE HARM
     A. Sponsor's own licensing prices this patent
     B. Sponsor's damages models in other matters show the
        harm is calculable
     C. Sponsor delayed — it has known since [date]
     D. Share loss is measured quarterly by Sponsor itself
IV.  THE EQUITIES FAVOR APPLICANT
     Investment, capacity, supply commitments, launch readiness
V.   THE PUBLIC INTEREST FAVORS ENTRY
     Price differential; access; Congress's purpose
VI.  ANY BOND MUST REFLECT APPLICANT'S LOST PROFITS

Drafting notes.

The evidence plan's lead times are why this starts early. A sponsor that begins the economics when the notice arrives has ninety days to produce eight weeks of work in three parallel workstreams.

The applicant's section III.A is frequently the strongest point. A sponsor that has licensed the patent has priced it, and price is the definition of an adequate legal remedy.

Section VI is not an afterthought. A bond reflecting the applicant's lost profits during an injunction is a very large number and can itself deter the motion.

11. At-risk launch memorandum

PRIVILEGED — BOARD MATERIAL
AT-RISK LAUNCH ANALYSIS — [Product]

1. POSTURE
   FDA licensure: [date]  Litigation status: __________
   180-day notice given: [date]  Earliest launch: [date]
   Preliminary injunction: [denied / not sought / pending]

2. UPSIDE
   Net revenue during the risk period: $________
   Market position value: $________
   First-mover / interchangeability considerations: ________

3. DOWNSIDE
   Probability of an adverse final judgment: ______%
   [Written assessment from trial and appellate counsel
   attached.]
   ** DAMAGES = SPONSOR'S LOST PROFITS **
   Sponsor's product revenue: $________/yr
   Sponsor's gross margin: ______%
   Units we would take: ________
   Duration of exposure: ______ months
   ESTIMATED LOST PROFITS EXPOSURE: $________
   Enhanced damages (willfulness): $________
   Fees under 35 U.S.C. § 285: $________
   Injunction / recall / supply disruption: $________
   TOTAL: $________
   **As a percentage of our enterprise value: ______%**

4. EXPECTED VALUE
   (1 − p) × upside − p × downside = $________

5. OTHER
   Insurance available: $________ [usually inadequate]
   Payer and provider commitments if withdrawn: ________
   Reputational and regulatory consequences: ________

6. RECOMMENDATION AND BOARD APPROVAL

Drafting notes.

Section 3's bolded line is the reason this memorandum exists. Biosimilar developers consistently model their own revenue as the exposure. The measure is the sponsor's lost profits, and for a $3 billion product taken at 20 percent share for eighteen months, that number is roughly $900 million at a 70 percent margin — frequently a multiple of the applicant's market capitalization.

Section 3's percentage-of-enterprise-value line is the sentence a board needs.

12. Settlement term sheet

SETTLEMENT TERM SHEET — [Sponsor] / [Applicant]
[Reference Product] — BLA No. [___]

1. ENTRY DATE. Applicant may commence commercial marketing on
   __________.

2. LICENSE. Non-exclusive license under the listed patents,
   effective on the Entry Date, [royalty-bearing at ___% of net
   sales / royalty-free].

3. INTERCHANGEABILITY. The license [does / does not] extend to
   an interchangeable presentation. If Applicant obtains an
   interchangeability determination, the Entry Date for that
   presentation is __________.

4. ACCELERATION. The Entry Date accelerates to the earliest of:
   (a) any third-party biosimilar launch;
   (b) a final judgment of invalidity, unenforceability, or
       non-infringement of all licensed patents;
   (c) [other defined events].

5. MOST FAVORED ENTRY. If Sponsor grants any other 351(k)
   applicant an earlier date, Applicant's date accelerates.

6. SUPPLY. [If applicable: Sponsor provides drug substance /
   fill-finish capacity on the terms in Exhibit __.]
   **INDEPENDENT VALUE ANALYSIS REQUIRED — SEE ANTITRUST
   MEMORANDUM.**

7. PTAB. Applicant [withdraws / maintains] pending petitions.

8. DISMISSAL. The action is dismissed [with] prejudice.

9. REPORTING. The parties shall make the filings required with
   the FTC and DOJ.

10. CONFIDENTIALITY. Subject to the reporting obligation and
    securities disclosure requirements.

Drafting notes.

Paragraph 3 is BPCIA-specific and frequently mishandled. A license silent on interchangeability leaves the most commercially valuable presentation unlicensed, and the parties then litigate again.

Paragraph 6 is the antitrust flashpoint in this sector. Supply arrangements between a sponsor and a biosimilar developer have obvious independent value — capacity is scarce and expensive — and precisely because they are commercially sensible, they must be priced at arm's length with a documented analysis prepared before signing, under the framework of FTC v. Actavis, Inc., 570 U.S. 136 (2013).

Paragraph 2's royalty-bearing default distinguishes these settlements from most generic ones and reflects the different economics.

13. Day-count calendar

BPCIA CALENDAR — [Program]
Owner: __________

DAY   EVENT                                   DUE      DONE
  0   FDA accepts the 351(k) application     ______    [ ]
 20   Application + process disclosure        ______    [ ]
 20   Supplemental confidentiality proposed   ______    [ ]
 80   Sponsor's patent list                   ______    [ ]
140   Applicant's detailed statements + list  ______    [ ]
200   Sponsor's detailed reply                ______    [ ]
215   Negotiation period ends                 ______    [ ]
220   List exchange (if no agreement)         ______    [ ]
245   Immediate action filed                  ______    [ ]

APPLICANT-CONTROLLED
 __   180-day notice given                    ______    [ ]
 __   Earliest commercial marketing           ______    [ ]

PARALLEL TRACKS
 __   FDA action date (current estimate)      ______
 __   PTAB petition deadline (if any)         ______
 __   PTAB institution decision expected      ______
 __   District court trial date               ______
 __   12-year exclusivity expires             ______

CRITICAL DEPENDENCIES
- Notice timing depends on the FDA action date estimate;
  update whenever regulatory affairs revises it.
- Any process change after Day 20 must route to patent counsel
  BEFORE implementation.

Related documents

This toolkit is general information, not legal advice, and does not create an attorney-client relationship. Templates require adaptation by counsel to the product, the patent estate, and the regulatory posture.